A retrospective study of the latest results found in Europe to carry out anti HER2 therapy, such as widely used in the treatment of breast c
A retrospective study of the latest results found in Europe to carry out anti HER2 therapy, such as widely used in the treatment of breast cancer trastuzumab (Hessaitin), a small part of the progress of phase specific HER2 gene mutation in non-small cell lung cancer (NSCLC) patients have antitumor effect. Although more than 20% of breast cancer patients have a high expression of HER2 protein caused by genetic alterations, only 1-2% of patients with lung cancer have mutations in the HER2 gene. However, mutations in this gene can lead to sustained activation of the protein, so that tumor cells survive and stimulate their growth.
This is by far the largest study of the efficacy of anti HER2 drugs in patients who have completed standard initial chemotherapy and have a rare mutation. The results of the study, published in the Journal of Clinical Oncology, suggest that HER2 gene testing is valuable in identifying patients who may benefit from this treatment. The first author of the study, Professor of French Toulouse Larrey hospital Julien Mazi res lung disease, (MD, PhD) said: our study showed that many patients with HER2 mutations may benefit from anti HER2 drug treatment. "Although prospective clinical trials are needed to confirm the efficacy, we hope that based on this study and other studies, the expression of HER2 gene may be considered in the future. Lung cancer is the leading cause of cancer deaths worldwide, with only 1/7 of patients surviving for 5 years after diagnosis.
In recent years, the deepening of the molecular recognition of lung cancer on personalized medicine era, according to the key cancer gene mutation in the treatment plan, brings the hope to obtain a better therapeutic effect. These key mutations are known as "drive mutations" because they trigger and stimulate the growth of cancer cells. There are many anti HER2 drugs, such as trastuzumab, pertuzumab, lapatinib, has been approved for the treatment of other types of cancer, so HER2 is a promising therapeutic target. Early studies of lung cancer in patients with abnormal expression of HER2 (due to the additional replication of the HER2 gene) showed that anti HER2 therapy may benefit patients. However, there are few studies on the efficacy of this treatment in patients with HER2 mutations.
In the study, 3800 () of 65 NSCLC patients diagnosed in France, Spain, and Switzerland detected HER2 mutations. 65 of the patients with lung adenocarcinoma, most of whom were women (with a median of 65), and nearly half were never smokers (with a total of 65 in the group of 34). About 50% of patients are in the IV stage of cancer. 16 patients (all patients had stage IV lung cancer with platinum alone or in combination with bevacizumab) anti HER2 drugs with one or more, such as afatinib, trastuzumab, Rapati Ni Ma Tai (Tykerb) and imatinib treatment. Trastuzumab is combined with chemotherapy drugs such as paclitaxel, carboplatin, vinorelbine Changchun or docetaxel combined with other three kinds of anti HER2 drugs administered alone treatment. 16 patients in 9 patients in the treatment of trastuzumab after the 1 course of tumor has narrowed, and 2 patients (1 treated with trastuzumab another with afatinib treated) shrink tumors in second courses of treatment. Another 3 patients had stable disease (tumor growth stopped). In these patients who benefited from anti HER2 therapy, the disease was delayed to an average of 5.1 months (progression free survival), which was about a factor of 2 of those who received 2-3 of conventional chemotherapy. Imatinib treated with 2 patients, 1 patients received imatinib treatment of Ma Tai, but the therapy did not prevent disease worsening.
FDA has not yet approved Ma Tai. In January, HER1 was allowed to be used in the treatment of patients with advanced NSCLC who had mutations in the EGFR protein associated with HER2. Mazi re doctor to predict more patients 1 years or 2 years of data can make use of anti HER2 drugs in this group of patients is possible. Although only 2% of lung cancer patients have mutations in the HER2 gene, there are thousands of patients in the United States each year. We are looking for more critical mutations in lung cancer and matching them with targeted drugs. Although still need convincing data, HER2 gene mutation may be the target of another drug treatment available, trastuzumab approved drugs. As for these mutations in patients bring reasonable treatment choice. Article from http://www.iwarmyou.com/gcp/